Sandbox Reserved 1701

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 42: Line 42:
==== Sodium Site ====
==== Sodium Site ====
-
The allosteric sodium site in class A GPCRs has been characterized as important in inactive state GPCR stabilization <ref name="Katritch">PMID:24767681</ref>. Katritch et al <ref name="Katritch">PMID:24767681</ref> describe that class A GPCRs lacking conserved D2.50 and other polar residues within the sodium pocket are typically inactive. The MRGPRX2 <scene name='90/904306/Sodium_site_2/1'>sodium binding site</scene> consists of conserved D2.50, or ASP-75, and GLY-116 compared to the [https://proteopedia.org/wiki/index.php/Neurotensin_receptor#sodium%20binding%20pocket previously conserved] polar residues in this binding pocket such as S3.39. Other class A GPCRs demonstrate a larger sodium binding pocket with a higher negative character allowing for a suitable environment for sodium ions to bind. In MRGPRX2, this sodium binding pocket lacks the same amount of <scene name='90/904306/Sodium_site_charge/2'>negative character</scene> with the shift to a glycine residue rather than serine. However, evidence suggests that sodium is still able to bind in X2's sodium binding site even with fewer conserved residues.
+
The allosteric sodium site in class A GPCRs has been characterized as important in inactive state GPCR stabilization <ref name="Katritch">PMID:24767681</ref>. Katritch et al <ref name="Katritch">PMID:24767681</ref> describe that class A GPCRs lacking conserved D2.50 and other polar residues within the sodium pocket are typically inactive. The MRGPRX2 <scene name='90/904306/Sodium_site_2/2'>sodium binding site</scene> consists of conserved D2.50, or ASP-75, and GLY-116 compared to the [https://proteopedia.org/wiki/index.php/Neurotensin_receptor#sodium%20binding%20pocket previously conserved] polar residues in this binding pocket such as S3.39. Other class A GPCRs demonstrate a larger sodium binding pocket with a higher negative character allowing for a suitable environment for sodium ions to bind. In MRGPRX2, this sodium binding pocket lacks the same amount of <scene name='90/904306/Sodium_site_charge/3'>negative character</scene> with the shift to a glycine residue rather than serine. However, evidence suggests that sodium is still able to bind in X2's sodium binding site even with fewer conserved residues.
<scene name='90/904306/Alignment_sodium/1'>Sodium Site Alignment</scene>
<scene name='90/904306/Alignment_sodium/1'>Sodium Site Alignment</scene>
Line 61: Line 61:
==== DRY/ ERC Motif ====
==== DRY/ ERC Motif ====
[[Image:Screen Shot 2022-03-15 at 10.23.20 AM.png|200px|left|thumb|'''Figure 4.''' ERC Motif]]
[[Image:Screen Shot 2022-03-15 at 10.23.20 AM.png|200px|left|thumb|'''Figure 4.''' ERC Motif]]
-
The E/DRY motif in most class A GPCRs is responsible for forming salt bridges with surrounding residues and TM6<ref name="Rovati">PMID: 17192495</ref>. These salt bridges maintain the inactive conformation of the receptor until ligand binding breaks the ionic "lock" from these interactions. MRGPRX2 has an <scene name='90/904306/Erc_motif_3/1'>ERC Motif</scene> rather than the typically [https://proteopedia.org/wiki/index.php/A_Physical_Model_of_the_%CE%B22-Adrenergic_Receptor#conserved%20DRY%20motif conserved E/DRY Motif]. The amino acid residue shift from TYR-174 to CYS-128 allows compaction of the helices in MRGPRX2 where the standard TYR physically pushes the TMD helices apart('''Figure 4'''). The conserved residues E and R still form salt bridges with nearby residues. This and the closer packing of the helices contribute to a less significant TMD conformational change upon ligand binding ('''Figure 10''').
+
The E/DRY motif in most class A GPCRs is responsible for forming salt bridges with surrounding residues and TM6<ref name="Rovati">PMID: 17192495</ref>. These salt bridges maintain the inactive conformation of the receptor until ligand binding breaks the ionic "lock" from these interactions. MRGPRX2 has an ERC motif rather than the typically [https://proteopedia.org/wiki/index.php/A_Physical_Model_of_the_%CE%B22-Adrenergic_Receptor#conserved%20DRY%20motif conserved E/DRY Motif]. The amino acid residue shift from TYR-174 to CYS-128 allows compaction of the helices in MRGPRX2 where the standard TYR physically pushes the TMD helices apart('''Figure 4'''). The conserved residues E and R still form salt bridges with nearby residues. This and the closer packing of the helices contribute to a less significant TMD conformational change upon ligand binding ('''Figure 10''').
<scene name='90/904306/Alignment_erc/2'>ERC/DRY Alignment</scene>
<scene name='90/904306/Alignment_erc/2'>ERC/DRY Alignment</scene>
Line 77: Line 77:
=====NPxxY Motif=====
=====NPxxY Motif=====
-
The residues in the <scene name='90/904306/Npxxy_motif/4'>NPxxY Motif</scene> are pivotal for receptor activation in all Class A GPCRs. This motif is conserved in the MRGPRX2 receptor with residues VAL-231, ASP-75, ASN-275, and TYR-279.
+
The residues in the <scene name='90/904306/Npxxy_motif/5'>NPxxY motif</scene> are pivotal for receptor activation in all Class A GPCRs. This motif is conserved in the MRGPRX2 receptor with residues VAL-231, ASP-75, ASN-275, and TYR-279.
=====CWxP Motif=====
=====CWxP Motif=====
-
The <scene name='90/904306/Cpxw_motif_2/1'>CWxP Motif</scene> is almost fully conserved except for TRP-236, or the toggle switch, which is replaced with GLY-236. CYS-235, LEU-237, and PRO-238 are all conserved. CYS6.47 may play a fundamental role in GPCR activity by participating in the rearrangement of TM6 and TM7 upon receptor activation<ref name="Olivella>PMID:23497259</ref>. This residue's role is supported by its conservation in MRGPRX2 as it is a functional GPCR.
+
The <scene name='90/904306/Cpxw_motif_2/2'>CWxP motif</scene> is almost fully conserved except for TRP-236, or the toggle switch, which is replaced with GLY-236. CYS-235, LEU-237, and PRO-238 are all conserved. CYS6.47 may play a fundamental role in GPCR activity by participating in the rearrangement of TM6 and TM7 upon receptor activation<ref name="Olivella>PMID:23497259</ref>. This residue's role is supported by its conservation in MRGPRX2 as it is a functional GPCR.
=== Ligands ===
=== Ligands ===

Revision as of 20:42, 18 April 2022

MRGPRX2 Human Itch G-Protein Coupled Receptor (GPCR)

PDB ID 7s8l

Drag the structure with the mouse to rotate

References

  1. Hauser AS, Attwood MM, Rask-Andersen M, Schioth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017 Dec;16(12):829-842. doi: 10.1038/nrd.2017.178. Epub, 2017 Oct 27. PMID:29075003 doi:http://dx.doi.org/10.1038/nrd.2017.178
  2. Basith S, Cui M, Macalino SJY, Park J, Clavio NAB, Kang S, Choi S. Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. Front Pharmacol. 2018 Mar 9;9:128. doi: 10.3389/fphar.2018.00128. eCollection, 2018. PMID:29593527 doi:http://dx.doi.org/10.3389/fphar.2018.00128
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 Cao C, Kang HJ, Singh I, Chen H, Zhang C, Ye W, Hayes BW, Liu J, Gumpper RH, Bender BJ, Slocum ST, Krumm BE, Lansu K, McCorvy JD, Kroeze WK, English JG, DiBerto JF, Olsen RHJ, Huang XP, Zhang S, Liu Y, Kim K, Karpiak J, Jan LY, Abraham SN, Jin J, Shoichet BK, Fay JF, Roth BL. Structure, function and pharmacology of human itch GPCRs. Nature. 2021 Dec;600(7887):170-175. doi: 10.1038/s41586-021-04126-6. Epub 2021, Nov 17. PMID:34789874 doi:http://dx.doi.org/10.1038/s41586-021-04126-6
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 Yang F, Guo L, Li Y, Wang G, Wang J, Zhang C, Fang GX, Chen X, Liu L, Yan X, Liu Q, Qu C, Xu Y, Xiao P, Zhu Z, Li Z, Zhou J, Yu X, Gao N, Sun JP. Structure, function and pharmacology of human itch receptor complexes. Nature. 2021 Dec;600(7887):164-169. doi: 10.1038/s41586-021-04077-y. Epub 2021, Nov 17. PMID:34789875 doi:http://dx.doi.org/10.1038/s41586-021-04077-y
  5. Kamato D, Thach L, Bernard R, Chan V, Zheng W, Kaur H, Brimble M, Osman N, Little PJ. Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, Galpha/q,11. Front Cardiovasc Med. 2015 Mar 24;2:14. doi: 10.3389/fcvm.2015.00014. eCollection, 2015. PMID:26664886 doi:http://dx.doi.org/10.3389/fcvm.2015.00014
  6. Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S. Action of molecular switches in GPCRs--theoretical and experimental studies. Curr Med Chem. 2012;19(8):1090-109. doi: 10.2174/092986712799320556. PMID:22300046 doi:http://dx.doi.org/10.2174/092986712799320556
  7. 7.0 7.1 Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in class A GPCR signaling. Trends Biochem Sci. 2014 May;39(5):233-44. doi: 10.1016/j.tibs.2014.03.002. Epub , 2014 Apr 21. PMID:24767681 doi:http://dx.doi.org/10.1016/j.tibs.2014.03.002
  8. Rovati GE, Capra V, Neubig RR. The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol. 2007 Apr;71(4):959-64. doi: 10.1124/mol.106.029470. Epub 2006 Dec , 27. PMID:17192495 doi:http://dx.doi.org/10.1124/mol.106.029470
  9. Naranjo AN, Chevalier A, Cousins GD, Ayettey E, McCusker EC, Wenk C, Robinson AS. Conserved disulfide bond is not essential for the adenosine A2A receptor: Extracellular cysteines influence receptor distribution within the cell and ligand-binding recognition. Biochim Biophys Acta. 2015 Feb;1848(2):603-14. doi: 10.1016/j.bbamem.2014.11.010., Epub 2014 Nov 16. PMID:25445670 doi:http://dx.doi.org/10.1016/j.bbamem.2014.11.010
  10. Olivella M, Caltabiano G, Cordomi A. The role of Cysteine 6.47 in class A GPCRs. BMC Struct Biol. 2013 Mar 15;13:3. doi: 10.1186/1472-6807-13-3. PMID:23497259 doi:http://dx.doi.org/10.1186/1472-6807-13-3
  11. 11.0 11.1 Porebski G, Kwiecien K, Pawica M, Kwitniewski M. Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) in Drug Hypersensitivity Reactions. Front Immunol. 2018 Dec 20;9:3027. doi: 10.3389/fimmu.2018.03027. eCollection, 2018. PMID:30619367 doi:http://dx.doi.org/10.3389/fimmu.2018.03027
  12. 12.0 12.1 12.2 McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, Dong X. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015 Mar 12;519(7542):237-41. doi: 10.1038/nature14022. Epub 2014 Dec 17. PMID:25517090 doi:http://dx.doi.org/10.1038/nature14022
  13. Navines-Ferrer A, Serrano-Candelas E, Lafuente A, Munoz-Cano R, Martin M, Gastaminza G. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep. 2018 Aug 2;8(1):11628. doi: 10.1038/s41598-018-29965-8. PMID:30072729 doi:http://dx.doi.org/10.1038/s41598-018-29965-8
Personal tools